Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now small index

Ablation clinical trials

4 of 5 indexed Ablation trials are currently recruiting.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Ablation: 5 US clinical trials tracked, 4 recruiting.

Ablation is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. The most active sponsor is Pulse Biosciences, running 2 of these trials.

Enrollment posture brief

Registry condition ablation

OPEN 4 | RECR 80% | LATE 0 | EARLY 0 | RANK #3391 | SPON 2

Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)

ACL Reconstruction80%Ablation (this)80%Abuse, Drug60%Acceptability60%Acral Lentiginous Melanoma20%
Open-enrollment share among volume-matched conditions near Ablation

Ablation lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Ablation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Ablation is recruiting above its size-band peers.

    4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Ablation research.

    Pulse Biosciences accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Ablation enrolment sits around 100 participants.

    Median target enrolment is 100 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.

  4. Ablation research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase Distribution

Phase data not available

Named interventions

Most-linked intervention names on Ablation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device Device
1 trials
TRANBERG® Transperineal Fusion Laser--Induced Thermal Therapy of Prostate Cancer (TPF-LITT) Device
1 trials
nPulse Vybrance Percutaneous Electrode System Device
1 trials
Peritorq Device
1 trials
CellFX® nsPFA™ Cardiac Surgery System Device
1 trials

US sites by state

Facility locations filed on Ablation trials. A trial with sites in several states counts in each.

Florida 3 trials
New York 2 trials
Michigan 2 trials
California 2 trials
Wisconsin 1 trials
Texas 1 trials
Tennessee 1 trials
South Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Ablation page

5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ablation condition card totals 5 registered trials; most-linked intervention Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.